We are serious about changing the face of medicine. As we pioneer new science and expand a diverse research pipeline, we launched The Lens: a thought-leadership platform to share our team’s expertise in precision medicine for oncology and rare diseases.
Browse our archive of blog posts and webinars below.
International Mastocytosis and Mast Cell Diseases Awareness Day 2022
October 17, 2022
Since early in our company’s history, we’ve been deeply committed to advancing care for systemic mastocytosis as we aim to address unmet patient needs. This…
Read moreAACR Annual Meeting 2022: Showcasing our Precision Therapy Pipeline
April 8, 2022
At the American Association for Cancer Research (AACR) Annual Meeting 2022, we’re presenting new clinical and preclinical data for multiple programs across our precision therapy…
Read moreImplementing a meaningful and sustainable equity, diversity and inclusion strategy
January 18, 2022 by Jessica Kline, Director of Internal Communications & Corporate Social Responsibility, and Rizwana Seeham, Senior Manager of GMP Quality Assurance & ED&I
Originally published on MassBio.org December 20, 2021 At Blueprint Medicines, we’ve been committed to equity, diversity, and inclusion (ED&I) since our company’s founding in 2011.…
Read moreThe right moment for thoughtful transition of leadership at Blueprint Medicines
January 12, 2022 by Jeff Albers and Kate Haviland
Last week, we announced that Jeff Albers, our Chief Executive Officer (CEO), has decided to step down and move into the position of Executive Chairman,…
Read moreBlueprint’s Biomarker Testing Program: KIT D816V Test Available for Eligible U.S. Patients Suspected of Having Systemic Mastocytosis
November 22, 2021 by Ruthvik Malladi, Associate Director, Precision Medicine
Receiving a timely diagnosis is difficult for many patients living with a rare disease. These challenges are particularly significant for systemic mastocytosis (SM), a rare…
Read moreFemale Leaders at Blueprint Medicines Bringing
Leadership across the Life Sciences Industry
October 22, 2021 by Jeff Albers
At Blueprint Medicines, we believe diversity is a core strength of our business. By drawing upon a range of backgrounds, experiences and perspectives, we strengthen…
Read moreOur first decade of innovation in precision medicine
April 21, 2021 by Fouad Namouni
This month marks 10 years since Blueprint Medicines began operations, and it’s a natural time to celebrate the science, patients and people who have made…
Read moreJoining Other Precision Medicine Stakeholders to Develop United Language for Testing
June 11, 2020 by Elissa Quinn, Associate Director, Precision Medicine
With more biomarker-targeted therapies becoming available, patient advocacy groups have increasingly talked about the challenge of confusing terminology for cancer testing. In March 2019, my…
Read moreASCO 2019: Advancing Cancer Treatment with Precision Therapies
May 31, 2019
At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…
Read moreBlueprint Medicines Recognizes International FOP Awareness Day
April 23, 2019
Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…
Read moreHow Our Research Platform Helped Accelerate the Discovery of BLU-667
April 10, 2019 by Jason Brubaker
Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…
Read moreBlueprint Medicines Introduces The Lens
January 2, 2019 by Marion Dorsch, Chief Scientific Officer
Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…
Read more